Mesothelioma Survival Rates by Treatment Type

The 12% five-year survival rate cited for mesothelioma is a population average. It includes people diagnosed at every stage, with every cell type, receiving every level of treatment, including none at all.

The number that matters is the one that reflects a specific person’s situation: their type of mesothelioma, their cell type, and the treatment they receive. The data below breaks survival down by each of these variables, drawing from SEER, NCI, and the results of major clinical trials.

Survival by Treatment Approach

These figures represent medians across published studies and clinical trials. Individual outcomes vary based on stage, cell type, overall health, and treatment center.

Chemotherapy

Standard first-line chemotherapy for pleural mesothelioma is pemetrexed combined with cisplatin or carboplatin. This regimen produces a response rate of approximately 41% and a median overall survival of 12 to 14 months.

Before immunotherapy became available in 2020, this was the only approved systemic treatment. It remains part of the standard of care, either alone or combined with immunotherapy.

For people who cannot receive immunotherapy due to autoimmune conditions or other factors, chemotherapy alone still offers a meaningful extension of life compared to best supportive care.

Immunotherapy

Immunotherapy has produced the most significant survival improvements in mesothelioma over the past five years.

Nivolumab Plus Ipilimumab (CheckMate-743)

The CheckMate-743 trial demonstrated an 18.1-month median survival with nivolumab plus ipilimumab, compared to 14.1 months for chemotherapy. The five-year data showed the benefit grew over time: 14% of people on immunotherapy were alive at five years versus 6% on chemotherapy.

The benefit was most pronounced for non-epithelioid cell types. People with sarcomatoid mesothelioma on immunotherapy had a median survival of 18.3 months, compared to 8.8 months on chemotherapy.

Pembrolizumab Plus Chemotherapy (KEYNOTE-483)

KEYNOTE-483 showed that adding pembrolizumab to chemotherapy produced a 52% response rate and a median survival of 17.3 months, versus 16.1 months for chemotherapy alone. The FDA approved this combination in September 2024.

Surgery

The role of surgery in mesothelioma depends heavily on the specific procedure, the surgeon’s experience, and the disease type.

Pleural Mesothelioma

Two main surgical approaches exist for pleural mesothelioma: pleurectomy/decortication (P/D) and extrapleural pneumonectomy (EPP).

The MARS 2 trial showed that adding extended pleurectomy/decortication to chemotherapy in a broad population did not improve survival. However, lung-sparing P/D at specialized centers continues to produce different outcomes in highly selected people, particularly those with epithelioid cell type and early-stage disease.

Peritoneal Mesothelioma: CRS/HIPEC

Cytoreductive surgery with heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma produces dramatically better outcomes than any other mesothelioma treatment.

The key variable is cytoreduction completeness. When surgeons remove all visible disease (CC-0 score), median survival reaches 104 months. When residual disease exceeds 2.5 cm (CC-2), median survival drops to 2.7 months.

Multimodal Treatment

Multimodal therapy combines two or more treatment types, typically surgery with chemotherapy and sometimes radiation.

The Hopkins perioperative immunotherapy trial and the Baylor-Duke NEMO trial are testing whether adding immunotherapy to the surgical approach can further improve outcomes. Early data is promising.

Survival by Cell Type

Cell type is one of the strongest predictors of how well treatment works.

The most important shift in recent years is for sarcomatoid mesothelioma. Historically, this subtype responded poorly to every treatment. CheckMate-743 showed that immunotherapy more than doubled median survival for this group (18.3 vs. 8.8 months), and ATOMIC-Meso quadrupled three-year survival.

Survival by Stage

Stage at diagnosis has an outsized impact on treatment eligibility. 65% of people with mesothelioma are diagnosed at Stage 3 or 4, limiting their options.

The relatively narrow gap between stages in this SEER data reflects the fact that even early-stage mesothelioma has limited five-year survival with standard treatment. The data also reflects that many people with early-stage disease receive aggressive multimodal treatment, which is not separated out in these population-level figures.